March 20, 2024
(Industry Intelligence Inc.)
–
The following are highlights from the Gerresheimer Q4 2023 Earnings Conference Call held on Feb. 22, 2024: Gerresheimer reports the pharma market is forecast to grow at a compound annual growth rate of 1.7% until 2028 according to IQVIA. The biologics market forecast to have a midterm compound annual growth rate of 15%. Half of new drug approvals globally are biologics, which is a highly attractive market for Gerresheimer. In the biologics sector, GLP-1 drugs are forecast to grow at 30%. Gerresheimer expects the segment to offer mid- and long-term growth opportunities. Gerresheimer has identified three growth drivers to help the company achieve its targeted compound annual growth rate of 10% plus. These include: Gerresheimer is collaborating with Aptar Digital Health to develop an integrated solution for cancer therapies. The solution includes Gerresheimer’s Gx SensAir for the subcutaneous administration for large molecule biologics connected to Aptar’s Digital Health platform. Gerrisheimer reports several of its facilities are undergoing large-scale expansion, driven by orders for medical devices and high-value biologics solutions. These include:
• The company’s classic portfolio of products.
• High-value solutions such as ready-to-fill vials, cartridges and syringes.
• Medical devices for biologics including pens, auto-injectors, and IP platforms for auto-injections and on-body drug delivery systems.
• Morganton, North Carolina, is expanding capacity for ready-to-fill vials.
• Gerresheimer is building a new production facility in Peachtree City, Georgia, for auto-injectors that will double capacity by the end of 2025.
• The Queretaro, Mexico, plant is adding 7,500 square-meters to produce high-quality prefilled glass syringes for injectable biologics.
• European facilities in Pfreimd, Skopje and Horsovsky Tyn expanding production for medical devices.
• The company’s Zhenjiang, China, facility is expanding to produce high-value, ready-to-fill vials.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
